Exchange: NASDAQ·Updated 07:57 PM EST

FLGT Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 05

Estimated EPS

-$0.65

Reported EPS

-$0.09

Surprise

+86.15%

Estimated Rev

$86.3M

Reported Rev

$90.41M

Surprise

+4.76%

• Reported GAAP EPS of -$0.09 down -164.29% YoY • Reported revenue of $90.41M up 7.54% YoY • Fulgent Genetics expects its collection rate and corresponding gross margin to improve as remaining billing-system customizations are completed, while research and development expenses are expected to increase as clinical trials progress.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.68
--
--
N/A
Q3 '26
-$0.65
-$0.09
86.15%
BEAT
Q2 '26
-$0.46
-$0.58
-26.09%
MISSED
Q1 '26
-$0.35
-$0.36
-3.40%
MISSED
Q4 '25
$0.03
$0.16
436.32%
BEAT

Advertisement|Remove ads.